Previous 10 | Next 10 |
- DSMB Reviewed Over 500 Patients’ Data in Second Interim Analysis to Assess Overall Benefit / Risk with Plinabulin in Second- and Third-Line, EGFR Wild-Type NSCLC - - Data Continue to Support Plinabulin’s Immune Mechanism-Targeted Patient Selection - NEW YORK, June 03, ...
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abst...
NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the United States Pate...
BeyondSpring Inc. (BYSI) Q4 2019 Earnings Conference Call April 30, 2020 08:00 AM ET Company Participants Caitlin Kasunich - Senior Vice President, KCSA Strategic Communications Lan Huang - Co-Founder, Chairman & Chief Executive Officer Ramon Mohanlal - Executive Vice Preside...
Image source: The Motley Fool. BeyondSpring Inc. (NASDAQ: BYSI) Q4 2019 Earnings Call Apr 30, 2020 , 9:00 a.m. ET Operator Continue reading
NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on F...
BeyondSpring (NASDAQ: BYSI ): Q4 GAAP EPS of -$0.52 misses by $0.12 . More news on: BeyondSpring Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN - - Initiated NDA Rolling Submission for Plinabulin for CIN in China in Q1 2020 - - On Track to Report Interim Analysis of Study ...
BeyondSpring ( BYSI +4.5% ) announces that the FDA has signed off on changing the primary endpoint of its Phase 3 clinical trial, Study 106 , evaluating lead drug Plinabulin for the prevention of chemo-induced neutropenia (abnormally low levels of a type of white blood cell called neutr...
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BeyondSpring Inc. (NASDAQ: BYSI) please note that in the fifth paragraph of the release, the correct percentage in the second sentence is 40.9, not 37.5 as previousl...
News, Short Squeeze, Breakout and More Instantly...
COPT Defense Properties of Beneficial Interest (CDP) is expected to report $0.64 for Q2 2024 Bank of Marin Bancorp (BMRC) is expected to report $0.19 for Q2 2024 Oak Ridge Financial Services Inc (BKOR) is expected to report for Q2 2024 D/B/A Centerspace (CSR) is expected to report $1....
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 12.4% to $0.0886 on volume of 1,366,648,994 shares Ascent Solar Technologies Inc (ASTI) rose 63.4% to $0.2147 on volume of 656,794,712 shares Pineapple Energy Inc. (PEGY) rose 61.4% to $...
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it hosted a virtua...